Repros Therapeutics Inc.® (Nasdaq: RPRX) announced that it remains on track for submission of a European centralized marketing authorization application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE